PerspectiveChromatin Therapeutics

Cancer Drug Discovery Faces the FACT

See allHide authors and affiliations

Science Translational Medicine  10 Aug 2011:
Vol. 3, Issue 95, pp. 95ps34
DOI: 10.1126/scitranslmed.3002822

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


In this issue of Science Translational Medicine, Gasparian et al. use a clever cell-based screen to identify a family of DNA-binding small molecules—curaxins—that inhibit tumor cell growth and division. The curaxins’ mechanism of action pinpoints a new chromatin-remodeling factor as a therapeutic target for cancer.


  • Citation: G. F. Draetta, R. A. DePinho, Cancer Drug Discovery Faces the FACT. Sci. Transl. Med. 3, 95ps34 (2011).

View Full Text

Stay Connected to Science Translational Medicine